NASDAQ:TENX

Tenax Therapeutics (TENX) Stock Forecast, Price & News

$0.30

+0.01 (+1.81%)

(As of 12:27 PM ET)

Compare

Today's Range: $0.30
▼
$0.31
50-Day Range: $0.28
▼
$0.41
52-Week Range: $0.25
▼
$4.30

Volume: 29,310 shs
Average Volume: 1.85 million shs
Market Capitalization: $7.26 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $6.00

Tenax Therapeutics MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 1,871.1% Upside
$6.00 Price Target
Short Interest: Healthy
0.10% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.44
Based on 2 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($0.46) to ($0.30) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.05 out of 5 stars

3.5

Analyst's Opinion

Consensus Rating
Tenax Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $6.00, Tenax Therapeutics has a forecasted upside of 1,871.1% from its current price of $0.30.
Amount of Analyst Coverage
Tenax Therapeutics has received no research coverage in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
0.10% of the outstanding shares of Tenax Therapeutics have been sold short.
Short Interest Ratio / Days to Cover
Tenax Therapeutics has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Tenax Therapeutics has recently increased by 114.02%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Tenax Therapeutics does not currently pay a dividend.
Dividend Growth
Tenax Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for TENX.

2.5

News and Social Media Coverage

News Sentiment
Tenax Therapeutics has a news sentiment score of 0.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.86 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Tenax Therapeutics this week, compared to 0 articles on an average week.
Search Interest
5 people have searched for TENX on MarketBeat in the last 30 days. This is an increase of 67% compared to the previous 30 days.
MarketBeat Follows
Only 1 people have added Tenax Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Tenax Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 2.00% of the stock of Tenax Therapeutics is held by insiders.
Percentage Held by Institutions
Only 1.67% of the stock of Tenax Therapeutics is held by institutions.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Tenax Therapeutics are expected to grow in the coming year, from ($0.46) to ($0.30) per share.
Price to Book Value per Share Ratio
Tenax Therapeutics has a P/B Ratio of 0.47. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Tenax Therapeutics (NASDAQ:TENX) Stock

Tenax Therapeutics, Inc. develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension. It develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is based in Chapel Hill, North Carolina.

TENX Price History

30 days | 90 days | 365 days | Advanced Chart

TENX Stock News Headlines

July 19, 2023 | finance.yahoo.com

Tenax Therapeutics Issued U.S. Patent for Oral Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

July 13, 2023 | finance.yahoo.com

TENX - Tenax Therapeutics, Inc.

September 27, 2023 | Micro-Cap Stock Trader (Ad)

U.S. drive to onshore battery supply chains could create big winners in lithium

Investor Find Lithium Gold and Crush the Bear Market with 32k Metric Tons

May 31, 2023 | tmcnet.com

Tenax Therapeutics Achieves Major Milestone as USPTO Grants Notice of Allowance for U.S. Patent Application Covering Use

May 31, 2023 | finance.yahoo.com

Tenax Therapeutics Achieves Major Milestone as USPTO Grants Notice of Allowance for U.S. Patent Application Covering Use of Oral Levosimendan (TNX-103) in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

May 22, 2023 | finance.yahoo.com

TENX: Prioritizing Levosimendan

April 12, 2023 | finance.yahoo.com

Tenax Therapeutics Prioritizes Development Of TNX-103 For Heart Failure

April 12, 2023 | finance.yahoo.com

Tenax Therapeutics Provides 2023 Business Update

September 27, 2023 | Micro-Cap Stock Trader (Ad)

U.S. drive to onshore battery supply chains could create big winners in lithium

Investor Find Lithium Gold and Crush the Bear Market with 32k Metric Tons

April 5, 2023 | finance.yahoo.com

TENX: Patents Guide the Way

March 31, 2023 | seekingalpha.com

TENX Tenax Therapeutics, Inc.

March 22, 2023 | finance.yahoo.com

Tenax Announces Issuance of U.S. Patent Covering Use of IV Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

March 8, 2023 | msn.com

Roth MKM Initiates Coverage of Tenax Therapeutics (TENX) with Buy Recommendation

March 7, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Abbott Labs (ABT), Tenax Therapeutics (TENX) and Day One Biopharmaceuticals (DAWN)

February 17, 2023 | finance.yahoo.com

Analysts Are Optimistic We'll See A Profit From Tenax Therapeutics, Inc. (NASDAQ:TENX)

February 15, 2023 | finance.yahoo.com

TENX: New Funding Puts Wind in the Sails

February 7, 2023 | finance.yahoo.com

Triangle pharma raising millions amid uncertain future

February 3, 2023 | marketwatch.com

Tenax Therapeutics Down 20% After Offering Gets Priced

February 3, 2023 | msn.com

Tenax Therapeutics stock dips after pricing $15.6M securities offering

February 3, 2023 | finance.yahoo.com

Tenax Therapeutics Announces Pricing of Approximately $15.6 Million Public Offering

February 2, 2023 | marketwatch.com

Tenax Therapeutics Shares Rise 73%, Co. Gets Patent for Hypertension Treatment

February 2, 2023 | finance.yahoo.com

Why Tenax Therapeutics Shares Are Gaining Today?

February 2, 2023 | investorplace.com

Why Is Tenax Therapeutics (TENX) Stock Up 149% Today?

February 1, 2023 | marketwatch.com

Tenax Shares Double After Hours, Co. Gets Patent for Use of IV Levosimendan in PH-HFpEF

February 1, 2023 | tmcnet.com

Tenax Granted Notice of Allowance for U.S. Patent Application Covering Use of IV Levosimendan in Pulmonary Hypertension

February 1, 2023 | finance.yahoo.com

Tenax Granted Notice of Allowance for U.S. Patent Application Covering Use of IV Levosimendan in Pulmonary Hypertension with Heart Failure and Preserved Ejection Fraction (PH-HFpEF)

January 25, 2023 | reuters.com

TENX.OQ - | Stock Price & Latest News | Reuters

See More Headlines

Receive TENX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Tenax Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

TENX Company Calendar

Last Earnings: 11/16/2021
Today: 9/27/2023
Next Earnings (Estimated): 9/28/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:TENX
CUSIP: N/A
CIK: 34956
Web: www.tenaxthera.com
Phone: 919-855-2100
Fax: 919-855-2133
Employees: 7
Year Founded: 1967

Price Target and Rating

Average Stock Price Forecast: $6.00
High Stock Price Forecast: $6.00
Low Stock Price Forecast: $6.00
Forecasted Upside/Downside: +1,920.2%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-11,050,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -96.87%
Return on Assets: -85.20%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 17.04
Quick Ratio: 17.04

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.65 per share
Price / Book: 0.46

Miscellaneous

Outstanding Shares: 23,862,000
Free Float: 23,385,000
Market Cap: $7.09 million
Optionable: Not Optionable
Beta: 2.07

Social Links

12 Stocks Corporate Insiders are Abandoning

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

Mr. Christopher T. Giordano (Age 48)
CEO, Pres & Director
Comp: $563.04k

Mr. Eliot M. Lurier CPA (Age 65)
CPA, Interim Chief Financial Officer
Comp: $221.7k

Dr. Stuart Rich M.D. (Age 73)
Chairman of Scientific Advisory Board, Chief Medical Officer & Director
Comp: $416k

Ms. Nancy J. M. Hecox
Exec. VP of Legal Affairs, Gen. Counsel & Corp. Sec.

Mr. Doug Randall
Exec. VP of Commercial & Bus. Operations

Dr. Douglas Hay
Sr. VP of Regulatory Affairs

Key Competitors

View All Competitors

TENX Stock - Frequently Asked Questions

Should I buy or sell Tenax Therapeutics stock right now?: 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Tenax Therapeutics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" TENX shares.
View TENX analyst ratings or view top-rated stocks.
What is Tenax Therapeutics' stock price forecast for 2023?: 2 Wall Street analysts have issued 1 year price targets for Tenax Therapeutics' stock. Their TENX share price forecasts range from $6.00 to $6.00. On average, they anticipate the company's share price to reach $6.00 in the next twelve months. This suggests a possible upside of 1,920.2% from the stock's current price.
View analysts price targets for TENX or view top-rated stocks among Wall Street analysts.
How have TENX shares performed in 2023?: Tenax Therapeutics' stock was trading at $2.2280 at the start of the year. Since then, TENX shares have decreased by 86.7% and is now trading at $0.2970.
View the best growth stocks for 2023 here.
When is Tenax Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, September 28th 2023.
View our TENX earnings forecast.
How were Tenax Therapeutics' earnings last quarter?: Tenax Therapeutics, Inc. (NASDAQ:TENX) announced its quarterly earnings results on Tuesday, November, 16th. The specialty pharmaceutical company reported ($3.00) EPS for the quarter, missing the consensus estimate of ($2.60) by $0.40.
When did Tenax Therapeutics' stock split?: Tenax Therapeutics shares reverse split on Wednesday, January 4th 2023. The 1-20 reverse split was announced on Wednesday, January 4th 2023. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, January 4th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What other stocks do shareholders of Tenax Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Tenax Therapeutics investors own include Sorrento Therapeutics (SRNE), AcelRx Pharmaceuticals (ACRX), Inovio Pharmaceuticals (INO), Idera Pharmaceuticals (IDRA), NVIDIA (NVDA), SCYNEXIS (SCYX), Verastem (VSTM), Bank of Hawaii (BOH), Gilead Sciences (GILD) and AVEO Pharmaceuticals (AVEO).
What is Tenax Therapeutics' stock symbol?: Tenax Therapeutics trades on the NASDAQ under the ticker symbol "TENX."
How do I buy shares of Tenax Therapeutics?: Shares of TENX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Tenax Therapeutics' stock price today?: One share of TENX stock can currently be purchased for approximately $0.30.
How much money does Tenax Therapeutics make?: Tenax Therapeutics (NASDAQ:TENX) has a market capitalization of $7.09 million.
How can I contact Tenax Therapeutics?: Tenax Therapeutics' mailing address is ONE COPLEY PARKWAY SUITE 490, MORRISVILLE NC, 27560. The official website for the company is www.tenaxthera.com. The specialty pharmaceutical company can be reached via phone at 919-855-2100, via email at jesse@sternir.com, or via fax at 919-855-2133.

This page (NASDAQ:TENX) was last updated on 9/27/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial